UChicago Team Engineers Gut Bacteria to Fight Liver Disease

Researchers have published a genetic toolkit for engineering hard-to-study bacteria that live in the human gut.

Updated on Nov. 19, 2026 in Science

Clear glass flasks of amber bacterial culture and a petri dish on a steel laboratory bench under even overhead light.
University of Chicago researchers published a genetic toolkit in Nature Microbiology for engineering gut bacteria that improved blood glucose and reduced inflammation in mice with fatty liver disease. AI Illustration. Upload story photo >

University of Chicago researchers published a genetic toolkit in Nature Microbiology for engineering a family of gut bacteria that produce metabolites linked to intestinal and metabolic health. In a mouse model, the engineered bacteria improved blood glucose balance and reduced inflammatory markers in mice with metabolic dysfunction-associated steatotic liver disease.

Why it matters

Gut microbes are difficult to study and modify with existing tools, which has limited scientists' understanding of how they protect health. A reliable way to engineer these bacteria could allow researchers to test whole families of microbes for beneficial effects.

The study was conducted in mice, with improvements in blood glucose balance and blood inflammatory markers in a model of metabolic dysfunction-associated steatotic liver disease. The extraction does not include specific numerical values, and human outcomes have not been reported.

The players

University of Chicago

A private research university in Chicago, Illinois, whose researchers conducted the study on engineered gut bacteria.

Mark Mimee

An assistant professor of microbiology and molecular engineering at the University of Chicago who served as senior author of the study.

The details

Researchers developed genetic tools to add features to a family of bacteria in the human gut microbiome that produce metabolites tied to intestinal and metabolic health. They engineered the bacteria to produce an additional immune protein that helps protect the gut lining, then gave them to mice with a model of metabolic dysfunction-associated steatotic liver disease.

Timeline

  1. The study was published in Nature Microbiology on November 19, 2026.

The Big Picture

The work builds on a growing effort to treat the gut microbiome as an engineerable platform rather than only a set of organisms to observe. It moves the field toward modifying entire bacterial families, which could change how researchers test microbes for metabolic and liver health.

For readers with metabolic conditions, this research does not yet change treatment options, since the work has only been tested in mice. It signals that engineered gut bacteria may eventually become a therapeutic approach, but any clinical use would require years of further testing.

The takeaway

Engineering gut bacteria is becoming more feasible, but results so far come from animal studies. Readers should treat claims about microbiome therapies as early-stage until human trials are reported.

Further reading

For related coverage, browse the Life Sciences section.

Source note: This article includes information reported by Phys.